FDA approves a new cancer drug, Vidaza, and two sNDAs, without going to ODAC. A date with ODAC may signal a weak case for drug approval, recent approval data indicate.
Also in this 8-page issue: Cooperative groups tell Congress that NCI’s $115 million in support for adult cancer clinical trials is “chump change.” Trials would close faster, report results sooner, if funding were increased, regulatory issues streamlined.
Larry Norton wins ASCO’s Karnofsky award.
Funding opportunities listed.
May issue of Business & Regulatory Report, 8 additional pages, included.
Trending Stories
- Beyond the $500B Stargate Project: The frontier of AI in oncology beckons
- What Trump’s pick of RFK Jr. means for cancer: Epidemics, HPV, stunted research
Former FDA Commissioner Scott Gottlieb expresses “deep concerns” - Trump 2016: A look back at the 45th president’s impact on oncology
- FDA grants Cytotron Breakthrough Device Designation for breast, liver and pancreatic cancers
- Felix Feng, GU cancer researcher who made fundamental discoveries in genomics, dies at 48
- Pediatric cancer research cut from spending legislation at last minute
Republicans quietly removed hard-won pediatric cancer bills